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The current opioid crisis in the USA arose from (at first) successful opioid pain
management in three waves, starting in the’90s. Today, USA patients consume opioid
drugs on a massive scale. Considering their potential for tolerance, as well as their
potential for lethality in relatively small overdose, the overuse of opioids form an
urgent threat to public health in the USA. Since the opioid crisis is a complex
phenomenon, several stakeholders are needed to tackle the problem. Both public
and private stakeholders should collaborate, e.g., in Public-Private Partnerships. Those
collaborations should focus on different aspects related to the opioid crisis such as
medical and societal (e.g., pain management process, including addressing opioid
use disorders), as well as economical and regulatory issues (e.g., incentivizing the
search for alternative non-addictive pain medication and banning aggressive marketing
tactics used by the pharmaceutical industry). Additionally, collaborations should cover
interdisciplinary education and training of various healthcare actors involved. In
conclusion, interdisciplinary collaboration on the various opioid abuse-related aspects is
urgently needed to tackle the opioid crisis in the USA.
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The opioid crisis is a byproduct, and more particularly, an adverse event of medical care (1).
The “opioid drug” class contains four categories according to the Centers for Disease Control
and Prevention (CDC): (1) natural opioid analgesics, such as morphine and codeine as well
as the semi-synthetic opioid analgesics such as oxymorphone, hydrocodone, oxycodone, and
hydromorphone, (2) the synthetic opioid methadone, (3) any other synthetic opioid, such as
fentanyl and tramadol, and (4) the illegally-made opioid heroin, synthesized from morphine (2).
Legally produced opioids are safe, highly effective analgesics and indispensable in modern pain
management, when used for a rightful purpose, during supervised therapy and handled by a
competent physician (3).
In 1986, the World Health Organization (WHO) proposed a three-step pain ladder for the
treatment of pain (4). The first step comprises non-opioid analgesics, such as paracetamol, aspirin,
and non-steroidal anti-inflammatory drugs (NSAIDs) for managing mild pain. In the second step
come weak-opioids like codeine or tramadol for moderate pain. The third step includes strong
opioids such as morphine, fentanyl, and oxycodone (5). Opioids should only be prescribed when
non-opioid analgesics and adjuvant therapies were unsuccessful. Additionally, opioids should be
dosed as low as possible, achieving pain relief with a minimal level of side effects (3).
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Dependence is a serious side effect associated with opioid use,
which can lead to compulsive use despite negative consequences,
a principal characteristic of substance abuse disorders as defined
by the Fifth Edition of the Disease and Statistical Manual of
Mental Disorders (DSM-5). Opioid use has led to a public health
crisis which is characterized by an exponential growth in people
suffering from opioid use disorders in several countries, notably
the USA. This opioid crisis has been described as the latest self-
inflicted threat to public health in the USAwhere drug overdoses,
predominantly caused by opioids, are the leading cause of death
for people under the age of 50 (1).
The USA opioid crisis rose from a perfect storm of events
with three major waves (Graph 1) (6). Since the 1990s, a first
wave resulted in increased deaths related to natural and semi-
synthetic prescription opioids (7). Since 2010, a second wave
was observed with a rapid increase in deaths caused by heroin
overdoses. Since 2013, a third wave began with overdose deaths
involving synthetic opioids, especially fentanyl (8). Together, this
has led to an exponential increase in deaths related to opioid
overdose and it has been widely debated what caused those waves.
The opioid crisis has been proposed to initially stem from
efforts to address the problem of under-treatment of pain, which
motivated practice and policy shifts (9). In the early 1990s,
the number of opioid prescriptions increased consequently,
not only for the treatment of acute pain (10) but for chronic
pain as well (11). Given that up to eleven percent of chronic
pain patients using opioids were found to meet criteria for
substance abuse disorders (12), these practice and policy shifts
may readily explain the steady growth in prescription opioid
abuse. This was exacerbated by other factors. Pharmaceutical
companies interested in expanding their markets misused the
practice and policy shifts with aggressive marketing strategies
(13, 14). In 1996, an extended-release oxycodone formulationwas
introduced to the market that was proposed by the manufacturer
to be effective for 12 h while being less addictive (15). At the
same time, when patients still experienced pain, they were
advised to take higher doses, rather than taking the extended-
release oxycodone more frequently (16). This further nurtured
so called “pill mills,” physicians who prescribe opioids regardless
of medical need (17). Moreover, not all prescription opioids are
taken by pain patients. Particularly acute pain patients take on
average only one third of the prescription opioids (18). Each of
those leftover pills can be sold with substantial financial profit,
leading to an increased availability of prescription opioids for
non-medical use. Due to the disappearance of manufacturing
jobs, rising inequality, the economic crisis in 2008 and long-term
unemployment, the temptation to sell the drugs for cash or to
take them for emotional relief instead of physical pain, increased.
Moreover, some of the prescription opioid users discovered that
the time-release mechanism of slow-release oxycodone could
be defeated by crushing the pills and injecting or snorting
the now effectively short-acting and highly addictive opioid.
Discussions about how to misuse the prescription opioids and
their effects became public and spread quickly, especially through
the growing use of the internet (16). In 2010, the government
started to crack down on “pill mills” (17). Additionally, an abuse
deterrent formula for slow-release oxycodone was announced
as an attempt to meaningfully deter abuse by making it more
difficult to crush the pills (19). As a result of those actions, some
of the people addicted to prescription opioids changed to using
heroin, since it is easier to use and cheaper (20). Indeed, as much
as eighty percent of heroin users started with taking prescription
opioids (21). Compared to heroin, synthetic opioids are relatively
easy to produce and traffic in substantial quantities given their
very high potency. It is therefore not surprising that from 2014
onwards, the number of fentanyl-related deaths increased by
72% (22).
Pharmaceutical companies provide physicians with free drug
samples, including prescription opioids, for promotion purposes.
This is a common practice in the USA. While in the European
Union (EU), opioids are subject to legal measures since 1992,
so far, no initiative to ban the provision of free samples has
been introduced in the USA. Even though the difference in drug
marketing can be linked to different health care systems between
the EU and the USA, banning free drug samples should be
urgently considered by policymakers (13, 14). By now, opioids
belong to the most widely-prescribed drug classes in the USA.
The country faces an extreme situation since it constitutes only
five percent of the world’s population, but it consumes 56% of the
world’s opioid drugs (23).
MULTI-STAKEHOLDER COLLABORATIONS
NEEDED TO TACKLE THE OPIOID CRISIS
Opioid analgesic abuse is a complex and multifactorial problem.
No single stakeholder can solve this crisis independently (24).
In 2005, the Food and Drug Administration (FDA) transformed
the drug risks and benefits assessment and issued a series of
guidance and the so called “risk minimization action plans”
(RiskMAPs) including riskminimization tools offered to industry
in order to achieve “specific health outcomes related to known
safety risks” (25). In 2016, the FDA issued its Opioids Action
Plan (26), aiming to reduce opioid prescription behavior through
education programs. The corporate social responsibility of the
pharmaceutical industry in the USA lacks. In its Opioid Action
Plan, the FDA also aims to reexamine the underlying risk-
benefit paradigm for opioids (14, 27). The pharmaceutical
industry should contribute with its expertise in product abuse
risk assessment, product communication and education, and
cooperate with federal and state authorities, as well as with
law enforcement authorities (24). They should implement
product abuse and diversion procedures in their corporate
mission statement, comparable as what the European Federation
of Pharmaceutical Industries and Associations (EFPIA) have
introduced in the healthcare professional code (28).
Already in 2003, collaborative initiatives had been set
up to unite diverse investigator groups to cooperate in the
field of pain research, such as the Brain Research through
Advancing Innovative Neurotechnologies (BRAIN). Examples
of pain management partnerships include the Multidisciplinary
Approach to the Study of Chronic Pelvic Pain (MAPP) aiming
to define an imaging-based signature for pelvic pain, or the
Collaborative Health Outcomes Information Registry (CHOIR)
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wherein an open-source learning healthcare platform was used
as a basis to develop a deep signature of individual patients
across several dimensions of social, psychosocial, and physical
functioning. This registry generated new insights about what
leads to pain persistence and what drives pain in general.
However, the setup of those partnerships was not broadly
implemented (22) and certainly did not end the trend of the
significant increase in non-medical use of prescription opioid
analgesics in the USA.
In order to boost collaboration, President Obama dedicated
in 2016 more than 1 billion US Dollars to set up evidence-based
prevention programs to support monitoring of prescription
drugs, take-back events related to prescription drugs, and to
facilitate the access to the overdose reversal drug naloxone (29).
Tackling the prescription opioid abuse requires a joint effort of
multiple stakeholders involved in the pain management process.
Public-private partnership (PPP) models vary depending on the
type of participants, the funding, the mission, and objectives (30).
PPPs such as the International Rare Diseases Research
Consortium (IRDiRC) (31) could serve as a role model in
the fight against opioid addiction. The FDA could benefit
from close collaboration with industry to review the system
barriers and organizational issues in the regulatory system
and work toward official action to end the practice of
aggressive marketing strategies. The Orphan Products Grants
Program of IRDiRC integrates industry, regulatory agencies
and patient advocacy organizations to collaboratively develop
recommendations for improved R&D and guidelines, regulation
and patient involvement. The FDA jointly works with industry
to define incentives including expedited reviews of new drug
applications for alternative products, having tamper-resistant
properties and support in the development of risk management
plans (24). Furthermore, the reimbursement policies could be
a subject of the regulatory science-based consortia, aiming
to prevent addicted patients to turn to cheaper, but illegal
alternatives which are more lethal.
Collaborations should focus on various aspects related to the
pain management process, including addressing the industry’s
lack of interest to invest in developing non-addictive pain
medication and addressing opioid use disorders. Since deterring
data concerning the development of successful and failed pain
medication is one major stumbling block (32), PPPs can be
set up that focus on more precompetitive targets, such as the
development of data management tools, registries, and shared
databases. These data could facilitate the understanding of
heterogeneous patient groups and their characteristics when
integrated in clinical trials. Also developing biomarkers to stratify
patients for trials and demonstrating target engagement, applying
new technologies to facilitate pain medication discovery, creating
a research trial network, establishing objective pain sensitivity
measures, and reengineering preclinical platforms to improve
predictive efficacy are topics that can be the focus of early-
phase research PPPs. Further, developing subgroups of large
cohort studies and repurposing already existing compound,
doing molecular profiling to begin validating targets and working
on new chemical entities, developing new bioinformatics
tools for target discovery purposes and reverse and forward
translation, cellular and mechanistic studies are situated in
the precompetitive sphere. Another aim of PPPs could be to
screen research using preclinical addiction models with focus
on reproducibility and reliability of published data. Moreover,
PPPs might do research on pharmacogenetics of addiction
and focus on working on programs to deliver extended-release
formulations of buprenorphine (opioid to treat opioid addiction)
in hospital emergency units to prevent opioid overdose, drug-
seeking, and drug-taking behavior (32).
Depending on the objectives of the partnership, public
and private constituencies affected by this societal crisis
need to collaborate, such as healthcare practitioners,
patients, professional organizations, researchers, educators,
pharmaceutical manufacturers, insurers, public health
agencies, the criminal justice system, and various governmental
institutions at local, state, and federal level, such as the FDA,
the Office of National Drug Control Policy (ONDCP), the Drug
Enforcement Administration (DEA), and the Substance Abuse
and Mental Health Administration (SAMHSA) (24).
The National Institute on Drug Abuse (NIDA) focuses its
research toward new analgesics, alternative delivery systems
and formulations, treatment of opioid abuse and addiction,
and prevention of overdose deaths. The recommendations
formulated stipulate the need for collaboration for prevention,
education, and outreach (29, 33). The standard measure for
pain assessment currently available may lack adequacy or
accuracy. New evidence-based tools and technology platforms
could help to deliver information on how to better treat various
subpopulations of patients (34). Furthermore, registries should
be set up to gather and process data related to various drugs,
patient monitoring, expanded electronic medical records (EMR),
and therapy. The theoretical framework is present. However, the
concrete implementation of the collaboration between various
healthcare actors involved in pain management and treatment
of addiction in terms of (precompetitive) research, treatment,
prevention, and education is not adequate to tackle the growing
crisis (29).
More efforts are needed to investigate the development of
curricular core competencies in the field of pain management
and how to implement new educational approaches. Guidelines
and best practices related to risk assessment and management
as well as prescription behavior should be developed and
implemented in new educational approaches (29). Collaborations
should encompass education and training of multiple healthcare
disciplines. This new educational models should be taught to
the next generation of healthcare providers, including schools
of medicine, nursing, physical therapy, and dentistry as well
as part of a continuous learning track for all healthcare
actors (29).
The search for innovative drugs with reduced abuse, tolerance,
and addiction risk is situated in a more competitive environment
and will require specific incentives for the pharmaceutical
industry to collaborate (30, 32). Abuse-deterrent formulations are
used in less than three percent of the cases, most likely due to
their high price. Pharmaceutical companies might be reluctant to
invest in developing them, when payers are not incentivized to
cover such medication. PPPs, driven by the industry as they carry
Frontiers in Medicine | www.frontiersin.org 3 May 2019 | Volume 6 | Article 106
Bolliger and Stevens Opioid Crisis in the USA
the burden for this crisis, should develop assisted funding systems
for developing alternative drugs.
Investigating how to improve and speed up the regulatory
system as well as pricing and reimbursement policies, is hence
another key approach to collaborate with each other.
CONCLUSION
The opioid crisis is of complicated and multifaceted nature
that calls for urgent collaborative action. An interdisciplinary
approach is needed by engaging several disciplines. Various types
of PPPs should be set up to focus on research, training, and
education. The research PPPs encompass early-phase research
developing tools, technologies, and platforms to accelerate the
drug development process, as well as the more competitive
task of developing new pain medication and also defining the
strategies, medication, and behavioral practices to treat opioid
use disorders. Training and education partnerships aim to
educate the various healthcare actors involved to implement
these strategies and best practices in the healthcare system (32).
The role of participation of patients, both those addicted due to
physical and psychological pain, therein is pivotal.
PPPs are a tool, not an objective per se. The key stakeholders
involved, each with their accompanying expertise, resources, and
experiences are essential to implement the changes needed to
tackle this public health crisis. Not one actor is solely responsible
for all aspects of this opioid crisis, however, the classical roles
of the various actors, such as the pharmaceutical industry, the
nonprofit sector, academia, and the government needs to be
reviewed with respect to the challenges faced (24). Successful
collaborations are built upon trust, clear rules and agreements
on the mission, the project objectives, the responsibilities of
the different stakeholders, and a good definition of the key
performance indicators that will be used to measure the PPP’s
success (24, 35). All need to work cooperatively to protect the
public interest.
Regardless of promising outcomes of PPPs, the National
Institute of Health (NIH) must remain critical and take ethical
considerations into account when accepting any sort of support
from companies of the e.g., pharmaceutical sector, since they have
contributed to a large extent to the opioid crisis (14, 36).
It can be concluded that despite novel approaches and
alternate formulations being developed to address the opioid
addiction, more resources are needed and the urgent situation of
the opioid crisis in the USA calls for more attention (32).
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APPENDIX
Graph 1 Three waves of the increasing opioid crisis (6).
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